GlassScriptPhysician profile
Ziad Ismael
NPI 1417096454
$1,214.70
in general payments reported to CMS, 2019-2025
14 companies · $83.13 in 2025
The $83.13 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2021: $37.56 · 2022: $24.63 · 2023: $88.23 · 2024: $169 · 2025: $83.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $228.02 | 2019 | |
| Intuitive Surgical, INC. | $190.77 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $90.34 | 2019 | |
| Genentech USA, INC. | $89.12 | 2019 | |
| Pfizer INC. | $79.34 | 2019-2024 | |
| Electromed, INC. | $72.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.98 | 2019 | |
| Merck Sharp & Dohme LLC | $67.52 | 2019-2025 | Zerbaxa |
| Insmed, INC. | $65.79 | 2019-2023 | Arikayce |
| Gilead Sciences, INC. | $50.56 | 2019 | |
| Vapotherm INC | $38.38 | 2019-2021 | |
| Philips North America LLC | $37.59 | 2023 | |
| Livanova USA, INC. | $18.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Ismael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.